Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ina, Y
Right arrow Articles by Miyachi, A
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ina, Y
Right arrow Articles by Miyachi, A

Chest, Vol 98, 911-916, Copyright © 1990 by American College of Chest Physicians


ARTICLES

Antigen-presenting capacity in patients with sarcoidosis

Y Ina, K Takada, M Yamamoto, M Morishita and A Miyachi
Second Department of Internal Medicine, Nagoya City University Medical School, Japan.

Antigen-presenting capacity by monocytes and AMs was determined in 13 patients with sarcoidosis and nine healthy control subjects, using PPD as the antigen. The patients and healthy control subjects all had positive PPD skin tests. Monocytes from both the control subjects and the patients with sarcoidosis exhibited antigen-presenting capacity to autologous peripheral T-lymphocytes, without any significant difference between the two groups. The AMs from patients, but not control subjects, demonstrated antigen-presenting capacity to autologous peripheral T-lymphocytes. Antigen-presenting capacity by monocytes and AMs to lung T-lymphocytes was lower than to peripheral T-lymphocytes, but not significantly. Antigen-presenting capacity was not significantly different between patients with sarcoidosis who had positive and negative PPD skin tests. The mechanism of enhanced antigen- presenting capacity by AMs in sarcoidosis is uncertain at present, but no significant difference was observed in DR antigen expression on AMs between controls and patients with sarcoidosis, and the addition of exogenous IL-1 or IFN-gamma did not induce antigen-presenting capacity by AMs in controls, suggesting that neither increased DR antigen expression on AMs nor increased release of IL-1 or IFN-gamma from AMs is responsible. Thus, these results suggest that T-lymphocyte activation in sarcoidosis may in part be attributable to an enhanced antigen-presenting capacity by AMs.


This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
P. J. Foley, D. S. McGrath, E. Puscinska, M. Petrek, V. Kolek, J. Drabek, P. A. Lympany, P. Pantelidis, K. I. Welsh, J. Zielinski, et al.
Human Leukocyte Antigen-DRB1 Position 11 Residues Are a Common Protective Marker for Sarcoidosis
Am. J. Respir. Cell Mol. Biol., September 1, 2001; 25(3): 272 - 277.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J Wahlström, M Berlin, C M Sköld, H Wigzell, A Eklund, and J Grunewald
Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis
Thorax, April 1, 1999; 54(4): 339 - 346.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Chest Physicians.